Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MicuRx Pharmaceuticals has completed its Phase I trial for MRX-I, a development-stage antibiotic drug candidate.
Subscribe to our email newsletter
The oral oxazolidinone antibiotic targets infections due to multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
MicuRx president and chief executive officer Zhengyu Yuan said the results of the clinical study show that MRX-I may represent the next generation of safer oxazolidinone antibiotics, not offered in the field to date.
"Based on the positive results, we expect to initiate Phase 2 clinical trials in both the United States and China, to determine optimal dosing for MRX-I," Yuan added.
The double-blind study evaluated safety, tolerability and pharmacokinetics of MRX-I, both in a single ascending dosing of up to 1800mg, and in a 15-day multiple-dose regimens of twice-daily 600mg and 800mg.
MRX-I was well tolerated, with no evidence of myelosuppression and was well absorbed, with exposure levels similar to linezolid, the study reported.